

CONTACT:

U.S. Physical Therapy, Inc. Carey Hendrickson, Chief Financial Officer email: chendrickson@usph.com Chris Reading, Chief Executive Officer (713) 297-7000 Three Part Advisors Joe Noyons (817) 778-8424

U.S. Physical Therapy Reports Fourth Quarter and Full Year 2023 Results

Company Provides 2024 Guidance

Houston, TX, February 28, 2024 – U.S. Physical Therapy, Inc. ("USPH" or the "Company") (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today reported results for the fourth quarter and the full year ended December 31, 2023.

FINANCIAL HIGHLIGHTS

- Adjusted EBITDA ⁽¹⁾, a non-Generally Accepted Accounting Principles ("GAAP") measure, was \$77.7 million for the year ended December 31, 2023 ("Full Year 2023"), a \$4.1 million increase from the year ended December 31, 2022 ("Full Year 2022").
- Operating Results ⁽¹⁾, a non-GAAP measure, for Full Year 2023 were \$36.3 million, an increase of \$1.3 million from \$35.0 million for Full Year 2022. On a per share basis, Operating Results were \$2.56 in Full Year 2023 compared to \$2.70 in Full Year 2022, with the decrease attributable to the increase in shares outstanding associated with the Company's secondary offering completed in May 2023.
- Net income attributable to USPH's shareholders ("USPH net income"), a GAAP measure, was \$28.2 million for Full Year 2023 compared to \$32.2 million for Full Year 2022. USPH net income included a non-cash impairment charge, prior to allocation to minority interest and income taxes, of \$17.5 million in the three months ended December 31, 2023 ("Fourth Quarter 2023") and \$9.1 million in the three months ended December 31, 2022 ("Fourth Quarter 2022"). In accordance with GAAP, the revaluation of non-controlling interest, net of taxes, is not included in net income but is charged directly to retained earnings; however, this change is included in the computation of earnings per share. Earnings per share for Full Year 2023 were \$1.28 compared to \$2.25 for Full Year 2022.
- Adjusted EBITDA for Fourth Quarter 2023 was \$19.0 million, a \$1.1 million increase over Fourth Quarter 2022.
- Operating Results for Fourth Quarter 2023 were \$8.9 million, a \$1.3 million increase over Fourth Quarter 2022.
- USPH net income for Fourth Quarter 2023 was \$0.7 million compared to \$2.6 million for Fourth Quarter 2022, including the non-cash impairment charges previously mentioned in both periods. In accordance with GAAP, the revaluation of non-controlling interest, net of taxes, is not included in net income but is charged directly to retained earnings; however, this change is included in the computation of earnings per share. Loss per share for Fourth Quarter 2023 was \$0.38 compared to \$0.01 for Fourth Quarter 2022.
- Total net revenue for Fourth Quarter 2023 increased \$13.6 million, or 9.6%, to \$154.8 million.
- Net rate per patient visit for Fourth Quarter 2023 was \$103.68, which has increased sequentially each quarter since the second quarter of 2023.
- Average daily visits per clinic were 29.9 for the Fourth Quarter 2023 and 30.0 for Full Year 2023, both record-high average daily visits per clinic in the Company's history for each respective period. Total patient visits were 1,267,842 in Fourth Quarter 2023, a 10.0% increase from Fourth Quarter 2022. Full Year 2023 patient visits were 5,005,426, an 11.6% increase over Full Year 2022.
- Fourth Quarter 2023 gross profit was \$30.5 million, a \$2.7 million increase from Fourth Quarter 2022.

- During the Full Year 2023, the Company added 46 new clinics through acquisitions and de novos, and closed 15 clinics bringing its total clinic count to 671 as of December 31, 2023, as compared to 640 clinics on December 31, 2022.
- The Company's Board of Directors raised the Company's quarterly dividend rate from \$0.43 per share to \$0.44 per share, effectively immediately, and declared a quarterly dividend for the first quarter of 2024 at the higher rate.
- Management currently expects the Company's Adjusted EBITDA for 2024 to be in the range of \$80 million to \$85 million. See "Management Provides 2024 Guidance" below for more information.
- (1) See pages 12 and 13 of this release for the definition and reconciliation of non-GAAP Adjusted EBITDA and Operating Results to the most directly comparable GAAP measure.

MANAGEMENT'S COMMENTS

Chris Reading, Chief Executive Officer, said, "Our team finished the year strong with record physical therapy volume for each quarter of 2023 as well as the year. Injury prevention also finished the year with some acceleration in both progress and opportunity. Looking forward, we have a great balance sheet bolstered by our capital raise in 2023 and you will see us put that to good use this year attracting more partner-owners looking for a great home for their teams and companies. Our partners across the entirety of our Company make a huge difference for us and for that we are all grateful. While we have been operating in a changing and challenging environment, we have the people and the resources to continue to grow."

Carey Hendrickson, Chief Financial Officer, added, "We have tremendous confidence in our team to produce EBITDA growth in 2024, despite headwinds from the Medicare rate reduction, with continued progress in rate negotiations, growth in volumes at our existing clinics and a continued focus on cost efficiencies. We'll also benefit from a full year of operations from clinics we acquired in 2023 and a partial year of operations from acquisitions we expect to complete in 2024."

FOURTH QUARTER 2023 VERSUS FOURTH QUARTER 2022

Additional supplemental tables of financial and performance metrics are presented on page 14 of this release.

Physical Therapy Operations

	Fourth Quarter Ended December 31,					ce		
	2023			2022		\$	%	
			(In th	ousands, except	percen	tages)		
Revenue related to:								
Mature Clinics (1)	\$	112,721	\$	111,066	\$	1,655	1.5 %	
Clinic additions (2)		18,650		7,964		10,686	*	(6)
Clinics sold or closed (3)		81		1,116		(1,035)	*	(6)
Net patient revenue		131,452		120,146		11,306	9.4 %	
Other (4)		3,177		2,644		533	20.2 %	
Total		134,629		122,790		11,839	9.6 %	
Operating costs (4)		108,380		98,247		10,133	10.3 %	
Gross profit	\$	26,249		\$ 24,543	\$	1,706	7.0 %	
Financial and operating metrics (not in thouse	nds):							
Net rate per patient visit (1)	\$	103.68	\$	104.28	\$	(0.60)	(0.6)%	
Patient visits (1)		1,267,842		1,152,139		115,703	10.0 %	
Average daily visits per clinic (1)		29.9		29.1		0.8	2.7 %	
Gross margin		19.5%		20.0%				
Salaries and related costs per visit, clinics (5)	\$	59.72	\$	60.04	\$	(0.32)	(0.5)%	
Operating costs per visit, clinics (5)	\$	84.09	\$	84.05	\$	0.04	0.0 %	

(1) See Glossary of Terms - Revenue Metrics for definition.

(2) Clinic additions during the Full Year 2023 and Full Year 2022.

(3) Revenue from closed clinics includes revenues from the 15 and 16 clinics closed during the Full Year 2023 and Full Year 2022, respectively.

(4) Includes revenues and costs from management contracts.

(5) Excludes management contract costs.

(6) Not meaningful.

Net revenue from physical therapy operations increased \$11.8 million, or 9.6%, to \$134.6 million for the Fourth Quarter 2023 from \$122.8 million for the Fourth Quarter 2022. This increase was primarily due to a record-high average daily visits per clinic for a fourth quarter in the Company's history of 29.9 visits, and an increase in volume from the 31 net new clinics added since the comparable prior year period, partially offset by a decrease in net rate per patient visit. The number of patient visits increased 10.0% over the Fourth Quarter 2022, with visits at mature clinics up 2.2%.

Net rate per patient visit was \$103.68 for the Fourth Quarter 2023, sequentially improving from \$102.03 in the second quarter of 2023 and \$102.37 in the third quarter of 2023. This compares to a \$104.28 net rate per patient visit in the Fourth Quarter 2022. The decrease in net rate in the Fourth Quarter 2023 compared to the same period in 2022 was primarily due to the combined Medicare rate reductions in 2022 and 2023. All other payor categories increased 2.1% on a combined basis as compared to the prior year.

Operating costs from physical therapy operations increased \$10.1 million, or 10.3%, to \$108.4 million in the Fourth Quarter 2023 from \$98.2 million in the Fourth Quarter 2022 driven by costs associated with the 31 net new clinics since the comparable prior year period as well as increased patient visits at mature clinics. Salaries and related costs per visit decreased to \$59.72 in the Fourth Quarter 2023 from \$60.04 in the Fourth Quarter 2022 while total operating costs per visit was roughly flat at \$84.09 as compared to \$84.05 over the same periods, respectively. Operating costs for mature clinics increased \$2.4 million, or 2.7%, in the Fourth Quarter 2023 as compared to the Fourth Quarter 2022.

Gross profit from physical therapy operations in the Fourth Quarter 2023 increased \$1.7 million, or 7.0%, to \$26.2 million from \$24.5 million in the Fourth Quarter 2022. The gross profit margin from physical therapy operations decreased slightly to 19.5% in the Fourth Quarter 2023 from 20.0% in the Fourth Quarter 2022.

Industrial Injury Prevention Services ("IIP")

	Fou	Fourth Quarter Ended December 31,				Variance					
	2023			2022		\$	%				
		(In thousands, except percentages)									
Net revenue	\$	20,172	\$	18,392	\$	1,780	9.7%				
Operating costs		15,905		15,104		801	5.3%				
Gross profit	\$	4,267	\$	3,288	\$	979	29.8%				
Gross margin		21.2%		17.9%							

IIP revenues increased \$1.8 million, or 9.7%, to \$20.2 million for the Fourth Quarter 2023 as compared to \$18.4 million for the Fourth Quarter 2022. IIP operating costs increased \$0.8 million, or 5.3%, versus the comparable prior year period. Gross profit from IIP operations in the Fourth Quarter 2023 increased \$1.0 million, or 29.8%, to \$4.3 million from \$3.3 million in the Fourth Quarter 2022. The gross profit margin from IIP operations increased to 21.2% in the Fourth Quarter 2023 from 17.9% in the Fourth Quarter 2022.

Corporate Office and Other Expenses

Corporate costs increased \$2.0 million, or 16.6%, to \$13.9 million in the Fourth Quarter 2023 from \$11.9 million in Fourth Quarter 2022 with an increase in support costs related to the larger number of clinics and the timing of certain expenses.

A non-cash impairment charge of \$17.5 million was recognized during the Fourth Quarter 2023 related to a reporting unit in the Company's IIP segment. This compares to a \$9.1 million non-cash impairment charge in the comparable prior year period related to the same reporting unit.

Operating loss was \$0.9 million for the Fourth Quarter 2023 compared to operating income of \$6.8 million for the Fourth Quarter 2022. Excluding the non-cash impairment charge of \$17.5 million in the Fourth Quarter 2023 and \$9.1 million in the Fourth Quarter 2022, operating income was \$16.6 million and \$15.9 million over the same periods, respectively.

Total other income (expense), net, was \$1.0 million in the Fourth Quarter 2023 compared to (\$2.2) million in the Fourth Quarter 2022.

- Interest expense, net of \$0.9 million savings from an interest rate swap arrangement, was \$2.0 million for the Fourth Quarter 2023 compared to \$2.2 million in the Fourth Quarter 2022. The interest rate on the Company's term loan was 4.7% for the Fourth Quarter 2023, with an all-in effective interest rate, including all associated costs, of 5.4%.
- Interest income from investing excess cash (primarily proceeds from the secondary offering sale of the Company's stock completed in May 2023) in a high-yield savings account was \$1.6 million during the Fourth Quarter 2023.

- The Company revalued the contingent earn-out consideration related to certain acquisitions and recognized \$1.7 million of expense (an increase in the related liability) in the Fourth Quarter 2023 compared to income of \$0.5 million (a decrease in the related liability) in the Fourth Quarter 2022.
- The revaluation of a put-right liability resulted in \$2.9 million of income (a decrease in the related liability) for the Fourth Quarter 2023 compared to \$0.8 million of expense (an increase in the related liability) for the Fourth Quarter 2022. The put-right, which expires in November 2026, relates to the potential future purchase of a company that provides physical therapy and rehabilitation services to hospitals and other ancillary providers in a distinct market area.

The provision for income taxes was \$1.4 million in the Fourth Quarter 2023 compared to \$1.2 million during the Fourth Quarter 2022.

USPH Net Income and Non-GAAP Measures

Net income (loss) attributable to non-controlling interest (temporary and permanent) was \$1.9 million in the Fourth Quarter 2023 compared to (\$0.7) million in the Fourth Quarter 2022.

USPH net income was \$0.7 million for the Fourth Quarter 2023 as compared to \$2.6 million for the Fourth Quarter 2022 while loss per share was \$0.38 and \$0.01 over the same periods, respectively. USPH net income included a non-cash impairment charge, prior to allocation to minority interest and income taxes, of \$17.5 million in the Fourth Quarter 2023 (\$9.1 million net of \$5.2 million allocated to minority interest and \$3.1 million of income tax) and \$9.1 million in the Fourth Quarter 2022 (\$4.7 million net of \$2.7 million allocated to minority interest and \$1.6 million of income tax).

Non-GAAP Adjusted EBITDA increased \$1.1 million to \$19.0 million for the Fourth Quarter 2023 from \$17.9 million for the Fourth Quarter 2022, while non-GAAP Operating Results increased \$1.3 million to \$8.9 million, or \$0.59 per share, in the Fourth Quarter 2023 from \$7.5 million, or \$0.58 per share, in the Fourth Quarter 2022. The increase in both non-GAAP Adjusted EBITDA and Operating Results was primarily associated with clinic additions since the comparable prior year period and increased volume at mature clinics.

See pages 12 and 13 of this release for the definition and reconciliation of Adjusted EBITDA and Operating Results to the most directly comparable GAAP measure.

FULL YEAR 2023 VERSUS FULL YEAR 2022

Total net revenue for the Full Year 2023 increased \$51.7 million, or 9.3%, to \$604.8 million from \$553.1 million for the Full Year 2022 while operating costs increased \$42.2 million, or 9.6%, to \$483.3 million from \$441.1 million over the same periods, respectively. Gross profit for the Full Year 2023 was \$121.5 million, or 20.1% of net revenue, compared to \$112.0 million for the Full Year 2022, or 20.3% of net revenue.

Revenues from physical therapy operations increased \$50.5 million, or 10.6%, to \$526.5 million in Full Year 2023 compared to \$476.1 million in Full Year 2022. This increase was primarily due to a record-high average daily visits per clinic for a full year in the Company's history of 30.0 visits, and an increase in volume from the 31 net new clinics added since the comparable prior year period, partially offset by a decrease in net rate per patient visit to \$102.80 for Full Year 2023 from \$103.63 for Full Year 2022. Gross profit from physical therapy operations increased \$9.0 million, or 9.4%, to \$105.1 million for Full Year 2023 from \$96.1 million for Full Year 2022 while the gross profit margin from physical therapy operations decreased slightly to 20.0% for Full Year 2023 from 20.2% for Full Year 2022.

Revenues from IIP increased \$1.2 million to \$78.3 million for Full Year 2023 from \$77.1 million for Full Year 2022. Gross profit from IIP operations increased \$0.5 million, or 3.0%, to \$16.4 million for Full Year 2023 from \$16.0 million for Full Year 2022 while the gross profit margin from IIP operations increased slightly to 21.0% for Full Year 2023 from 20.7% for Full Year 2022.

Corporate office costs were \$52.0 million, or 8.6% of net revenue, in Full Year 2023, compared to \$46.1 million, or 8.3% of net revenue, in Full Year 2022, with an increase in support costs related to the larger number of clinics.

Operating income was \$52.1 million for Full Year 2023 compared to \$56.8 million for Full Year 2022, including the non-cash impairment charge of \$17.5 million in Full Year 2023 and \$9.1 million in Full Year 2022.

Other expenses increased \$1.5 million to \$2.7 million in 2023 from \$1.2 million in 2022 primarily due to higher interest expense and expense related to fair value adjustments of certain contingent liabilities partially offset by income related to the revaluation of a put liability and interest income from investing excess cash associated with proceeds from the Company's secondary offering completed in May 2023.

The provision for income tax was \$12.2 million for Full Year 2023 and for Full Year 2022. The effective tax rate was 30.1% and 27.4% over the same periods, respectively. The Full Year 2023 includes an adjustment of \$1.0 million related to the return to provision analysis for such period.

USPH net income was \$28.2 million for the Full Year 2023 as compared to \$32.2 million for the Full Year 2022 while earnings per share was \$1.28 for Full Year 2023 compared to \$2.25 for Full Year 2022. USPH net income included a non-cash impairment charge, prior to allocation to minority interest and income taxes, of \$17.5 million in the Fourth Quarter 2023 (\$9.1 million net of \$5.2 million allocated to minority interest and \$3.1 million income tax) and \$9.1 million in the Fourth Quarter 2022 (\$4.7 million net of \$2.7 million allocated to minority interest and \$1.6 million income tax).

Non-GAAP Adjusted EBITDA increased \$4.1 million to \$77.7 million for Full Year 2023 from \$73.7 million in Full Year 2022 while non-GAAP Operating Results increased \$1.2 million to \$36.3 million, or \$2.56 per share, in Full Year 2023 from \$35.0 million, or \$2.70 per share, in the Full Year 2022. The increase in both non-GAAP Adjusted EBITDA and Operating Results was primarily associated with clinic additions since the comparable prior year period and increased volume at mature clinics.

See pages 12 and 13 of this release for the definition and reconciliation of Adjusted EBITDA and Operating Results to the most directly comparable GAAP measure.

For additional information on full year 2023 results, please refer to the Company's Annual Report on Form 10-K which is expected to be filed with the Securities and Exchange Commission on February 29, 2024.

BALANCE SHEET AND CASH FLOW

Total cash and cash equivalents were \$152.8 million as of December 31, 2023, compared to \$31.6 million as of December 31, 2022. Additionally, the Company had \$144.4 million of outstanding borrowings and \$175.0 million in available credit under its credit facilities as of December 31, 2023, compared to \$179.1 million of outstanding borrowings and \$144.0 million in available credit under its credit facilities facilities as of December 31, 2022.

On May 30, 2023, the Company completed a secondary offering of its common stock resulting in net proceeds of \$163.6 million after deducting fees associated with the transaction. A portion of the net proceeds was used to repay the \$35.0 million then outstanding under the Company's credit facility while the remainder is expected to be used primarily for acquisitions. The Company's cash is currently invested in a high-yield savings account which generated interest income of approximately \$3.8 million in 2023.

ACQUISITION ACTIVITIES

The Company is in various stages of completing several acquisitions that management expects to close in or shortly after the first half of 2024. The Company's strategy is to continue acquiring outpatient physical therapy practices, develop outpatient physical therapy clinics as satellites in existing partnerships, and continue acquiring companies that provide or serve the Company's industrial injury prevention services.

QUARTERLY DIVIDEND

The Company's Board of Directors increased the Company's quarterly dividend on February 27, 2024, from \$0.43 per share to \$0.44 per share. The Board of Directors subsequently declared a quarterly dividend of \$0.44 per share payable on April 5, 2024, to shareholders of record on March 12, 2024.

2024 EARNINGS GUIDANCE

Management expects the Company's Adjusted EBITDA for 2024 to be in the range of \$80 million to \$85 million. The previously announced Medicare rate reduction of approximately 3.5% effective January 1, 2024, is expected to reduce the Company's revenue by approximately \$6.0 million in 2024 as compared to 2023, which equates to an EBITDA reduction of approximately \$5.3 million net of non-controlling interests. Management expects to more than offset the decreases in revenue and EBITDA related to the Medicare rate reduction from:

- the full-year impact of rate negotiations in commercial and other payor categories completed during 2023
- the partial-year impact of rate negotiations in commercial and other payor categories expected to be completed during 2024
- volume increases at the Company's existing clinics
- continued discipline in expense control
- full-year contribution from acquisitions completed in 2023; and,

■ partial-year impact of EBITDA from acquisitions expected to be completed during or shortly after the first half of 2024.

As noted previously, the Company is currently in the process of completing several acquisitions that are expected to close in or shortly after the first half of 2024. The guidance range includes the expected EBITDA contribution from such acquisitions.

The annual guidance figures will not be updated unless there is a material development that causes management to believe that Adjusted EBITDA will be significantly outside the given range.

CONFERENCE CALL INFORMATION

U.S. Physical Therapy's management will host a conference call at 10:30 a.m. ET / 9:30 a.m. CT, on February 29, 2023, to discuss the Company's financial results for the fourth quarter and year ended December 31, 2023. Interested parties may participate in the call by dialing (800) 267-6316 (Primary) or (203) 518-9783 (Alternate) and conference ID of USPHQ423. Please call approximately 10 minutes before the call is scheduled to begin. To listen to the live call, go to the Company's website at <u>www.usph.com</u> at least 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, a playback of the conference call can be accessed until May 9, 2024, at the Company's website.

FORWARD LOOKING STATEMENTS

This press release contains statements that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of 1934, as amended. These statements contain forward-looking information relating to the financial condition, results of operations, plans, objectives, future performance and business of our Company. These statements (often using words such as "believes", "expects", "intends", "plans", "appear", "should" and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we expect. Included among such statements may be those relating to new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to:

- changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification and/or enrollment status;
- the impact of future public health crises and epidemics/pandemics, such as was the case with the novel strain of COVID-19 and its variants;
- revenue we receive from Medicare and Medicaid being subject to potential retroactive reduction;
- changes in reimbursement rates or payment methods from third party payors including government agencies, and changes in the deductibles and co-pays owed by patients;
- compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply;
- competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
- one of our acquisition agreements contains a put right related to a future purchase of a majority interest in a separate company;
- the impact of future vaccinations and/or testing mandates at the federal, state and/or local level, which could have an adverse impact on staffing, revenue, costs and the results of operations;
- our debt and financial obligations could adversely affect our financial condition, our ability to obtain future financing and our ability to operate our business;
- changes as the result of government enacted national healthcare reform;
- business and regulatory conditions including federal and state regulations;
- governmental and other third party payor inspections, reviews, investigations and audits, which may result in sanctions or reputational harm and increased costs;
- revenue and earnings expectations;
- some of our acquisition agreements contain contingent consideration, the value of which may impact future financial results;
- legal actions, which could subject us to increased operating costs and uninsured liabilities;
- general economic conditions, including but not limited to inflationary and recessionary periods;
- actual or perceived events involving banking volatility or limited liability, defaults or other adverse developments that affect the U.S. or international financial systems, may result in market wide liquidity problems which could have a material and adverse impact on our available cash and results of operations;
- our business depends on hiring, training, and retaining qualified employees

- availability and cost of qualified physical therapists;
- competitive environment in the industrial injury prevention services business, which could result in the termination or non-renewal of contractual service arrangements and other adverse financial consequences for that service line;
- our ability to identify and complete acquisitions, and the successful integration of the operations of the acquired businesses;
- impact on the business and cash reserves resulting from retirement or resignation of key partners and resulting purchase of their noncontrolling interest (minority interests);
- maintaining our information technology systems with adequate safeguards to protect against cyber-attacks;
- a security breach of our or our third-party vendors' information technology systems may subject us to potential legal action and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 of the Health Information Technology for Economic and Clinical Health Act;
- maintaining clients for which we perform management, industrial injury prevention related services, and other services, as a breach or termination of those contractual arrangements by such clients could cause operating results to be less than expected;
- maintaining adequate internal controls;
- maintaining necessary insurance coverage;
- availability, terms, and use of capital; and
- weather and other seasonal factors.

Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. For additional information regarding these and other risks and uncertainties, that could cause actual results to differ materially from those contained in our forward-looking statements, please refer to "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission ("SEC") on February 28, 2023 and any risk factors contained in subsequent quarterly and annual reports we file with the SEC. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement as a result of new information, future events, or otherwise, except as required by law.

GLOSSARY OF TERMS – REVENUE METRICS

Mature clinics are clinics opened or acquired prior to January 1, 2022, and are still operating as of the balance sheet date.

<u>Net rate per patient visit</u> is net patient revenue related to our physical therapy operations divided by total number of patient visits (defined below) during the periods presented.

Patient visits is the number of unique patient visits during the periods presented.

<u>Average daily visits per clinic</u> is patient visits divided by the number of days in which normal business operations were conducted during the periods presented and further divided by the average number of clinics in operation during the periods presented.

ABOUT U.S. PHYSICAL THERAPY, INC.

Founded in 1990, U.S. Physical Therapy, Inc. currently operates 673 outpatient physical therapy clinics in 42 states. The Company's clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically related injuries and rehabilitation of injured workers. In addition to owning and operating clinics, the Company manages 42 physical therapy facilities for unaffiliated third parties, including hospitals and physician groups. The Company also has an industrial injury prevention services business which provides onsite services for clients' employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.

More information about U.S. Physical Therapy, Inc. is available at <u>www.usph.com</u>. The information included on that website is not incorporated into this press release.

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

	Fourth Quarter Ended December 31,			ıber 31,	For the Year Ended December 31,			
	2023		2	022		.023		2022
Net patient revenue Other revenue	\$	131,452 23,349	\$	120,146 21,036	\$	514,556 90,246	\$	464,590 88,554
Net revenue		154,801		141,182		604,802		553,144
Operating cost: Salaries and related costs Rent, supplies, contract labor and other Provision for credit losses Total operating cost		90,633 32,080 1,572 124,285		82,317 29,678 1,356 113,351		353,390 123,731 <u>6,172</u> 483,293		319,191 116,381 5,548 441,120
Gross profit		30,516		27,831		121,509		112,024
Corporate office costs Impairment of goodwill and other intangible assets Operating (loss) income		13,901 17,495 (880)		11,925 9,112 6,794		51,953 17,495 52,061		46,111 9,112 56,801
Other (expense) income Interest expense, debt and other Interest income from investments Change in fair value of contingent earn-out consideration Change in revaluation of put-right liability Equity in earnings of unconsolidated affiliate Relief Funds Other		(2,010) 1,583 (1,747) 2,926 149 - 85		(2,239) 520 (776) 192 69		(9,303) 3,774 (1,550) 2,582 955 467 390		(5,779) 2,520 (5) 1,175 - 859
Total other (expense) income (Loss) income before taxes		986 106		(2,234) 4,560		(2,685) 49,376		(1,230) 55,571
Provision for income taxes Net (loss) income		1,399 (1,293)		<u>1,212</u> 3,348		<u>12,156</u> 37,220		12,164 43,407
Less: Net (income) loss attributable to non-controlling interest: Redeemable non-controlling interest - temporary equity Non-controlling interest - permanent equity		3,190 (1,241) 1,949		318 (1,059) (741)		(4,426) (4,555) (8,981)		(6,902) (4,347) (11,249)
Net income attributable to USPH shareholders	\$	656	\$	2,607	\$	28,239	\$	32,158
Basic and diluted (loss) earnings per share attributable to USPH shareholders (1)	\$	(0.38)	\$	(0.01)	\$	1.28	\$	2.25
Shares used in computation - basic and diluted		14,987		13,002		14,188		12,985
Dividends declared per common share	\$	0.43	\$	0.41	\$	1.72	\$	1.64

(1) See page 13 of this press release for the calculation of basic and diluted earnings per share.

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (IN THOUSANDS)

	Fourth Quarter Ended December 31,				For the Year Ended December 31,				
		2023	2022		2023			2022	
Net (loss) income Other comprehensive loss	\$	(1,293)	\$	3,348	\$	37,220	\$	43,407	
Unrealized (loss) gain on cash flow hedge Tax effect at statutory rate (federal and state)		(3,982) 1,017		(564) 144		(1,642) 420		5,378 (1,374)	
Comprehensive income (loss)	\$	(4,258)	\$	2,928	\$	35,998	\$	47,411	
Comprehensive income (loss) attributable to non-controlling interest		1,949	_	(741)	_	(8,981)		(11,249)	
Comprehensive income (loss) attributable to USPH shareholders	\$	(2,309)	\$	2,187	\$	27,017	\$	36,162	

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEET (IN THOUSANDS, EXCEPT SHARES AND PER SHARE AMOUNTS)

	Decen	nber 31, 2023	December 31, 2022	
ASSETS Current assets:				
Cash and cash equivalents	\$	152,825	\$	31,594
Patient accounts receivable, less provision for credit losses of \$2,736 and \$2,829, respectively	φ	51,866	ψ	51,934
Accounts receivable - other		17,854		16,671
Other current assets		10,830		11,067
Total current assets		233,375		111,266
Fixed assets:		233,375		111,200
Furniture and equipment		63,982		62,074
Leasehold improvements		46,941		42,877
Fixed assets, gross		110,923		104,951
Less accumulated depreciation and amortization		(84,821)		(80,203)
Fixed assets, net		26,102		24,748
Operating lease right-of-use assets		103,431		103,004
Investment in unconsolidated affiliate		12,256		12,131
Goodwill		509,571		494,101
Other identifiable intangible assets, net		109,682		108,755
Other assets		2,821		4,149
Total assets	\$	997,238	\$	858,154
LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST, USPH SHAREHOLDERS' EQUITY AND NON-CONTROLLING INTEREST Current liabilities:				
Accounts payable - trade	\$	3,898	\$	3,300
Accounts payable - due to seller of acquired business	Ψ	5,070	ψ	3,204
Accrued expenses		55,344		37,413
Current portion of operating lease liabilities		35,252		33,709
Current portion of term loan and notes payable		7,691		7,863
Total current liabilities		102,185		85,489
Notes payable, net of current portion		1,289		1,913
Revolving facility		1,207		31,000
Term loan, net of current portion and deferred financing costs		137,702		142,918
Deferred taxes		24,815		21,303
Operating lease liabilities, net of current portion		76,653		77,934
Other long-term liabilities		2,356		13,029
Total liabilities		345,000		373,586
		,		ŕ
Redeemable non-controlling interest - temporary equity		174,828		167,515
Commitments and Contingencies				
U.S. Physical Therapy, Inc. ("USPH") shareholders' equity:				
Preferred stock, \$.01 par value, 500,000 shares authorized, no shares issued and outstanding		-		-
Common stock, \$.01 par value, 20,000,000 shares authorized,				
17,202,291 and 15,216,326 shares issued, respectively		172		152
Additional paid-in capital		281,096		110,317
Accumulated other comprehensive gain		2,782		4,004
Retained earnings		223,772		232,948
Treasury stock at cost, 2,214,737 shares		(31,628)		(31,628)
Total USPH shareholders' equity		476,194		315,793
Non-controlling interest - permanent equity		1,216		1,260
Total USPH shareholders' equity and non-controlling interest - permanent equity		477,410		317,053
Total liabilities, redeemable non-controlling interest, USPH shareholders' equity and non-controlling interest - permanent equity	\$	997,238	\$	858,154

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (IN THOUSANDS)

December 31, 2023 December 31, 2023 December 31, 2023 Net income including non-controlling interest is not eash provided by operation activities: 15.697 41,202 Adjustment to exceede and income including non-controlling interest to not eash provided by operation activities: 15.697 41,203 Depresision on incomparation represent 7.226 7.544 Anonization of dot issue costs 420 305 Change in resolution of plot-diph lickility (2.282) 7.33 Change in resolution of plot-diph lickility (2.283) 7.33 Description of activity in macrosolidated affilia: 1606 (4.41) Impairment of good/milling activities 17.495 9.112 Other (5.59) (0.0279) 10.69 Decrease (increase) in accounts procirolitie (5.54) (0.0279) Increase in accounts recorrolitie 1.254 2.540 Other (5.54) (0.0279) Increase in accounts procirolitie 1.254 2.540 Other (5.54) (0.0279) Increase in accounts procirolitie 1.254 2.540 Procease					
Nationce including numerons is including non-controlling interest to pet (solid property intervities): S 37.20 S 4.4,007 Adjustments to proceed the income including non-controlling interest to pet (solid property intervities): 15.93 14.4,43 Provide of income including non-controlling interest to pet (solid property intervities): 6.112 5.548 Advisoration of data fight liability 6.233 5.548 Advisoration of data fight liability (2.530) 6.233 5.56 Change in revaluation of pat -fight liability (2.530) 6.233 6.511 Change in fight value of ording rate arrive of consideration 1.560 (2.500) Equity of contrings in numeronologic ording rate arrive ordin rate arrive ording rate arrive ording rate arrive ordi		Decembe	For the Yea r 31, 2023		ber 31, 2022
Adjustments to reconditioned income including non-controlling interest to net cash provided by operating activities: Depreciation and amountation 15.05 14.743 Provision for credit losss 6.172 5.484 Equity-based dwards compensation expanse 7.256 7.264 Adjust the formation of part-sphil lability (2.582) 9.5 Change in Addormal monosolitated affiliate (955) (1.175) Loss (gain) on sale of clinics and fitted asctt 166 (643) Impaint of goodenal and official sects 17.495 9.113 Impaint of goodenal and official sects 17.495 9.112 Increase in accounts receivable (5.643) (0.0279) Increase in accounts receivable (356) (077) Increase in accounts receivable (2.542) 2.549 Net cash portical construct and long-term assets (197) (5.544) Decrease (forcease) in patient accounts receivable (2.542) (2.978) Net cash portical sects (197) (5.540) Decrease (forcease) in obtain cases (2.252) (9.788) Procease of fixed assets (2.552) (9.788) <td></td> <td></td> <td></td> <td></td> <td></td>					
Depreciation and amonitration 15,065 14,743 Provision for credit losses 5,172 5,548 Equity-based awards compensation expense 7,236 7,264 Amonitration of fabri stage assis 4,30 6,300 Change in revolution of put stage in fair value of contingent car-avair consideration 12,530 6,2530 Clauge in prevaluation of put stage in fair value of contingent car-avair consideration 16,66 (643) Impainment of goodwall and other intangible assets 17,495 9,112 Change in operating to set and labilities (56,55) (10,277) Change in operating to set and labilities (56,55) (10,277) Change in operating to set and labilities 1,5 (7,755) Decrease (increase) in obsci masses 1,5 (7,755) Decrease (increase) in obsci masses 1,5 (7,755) Decrease (increase) in obsci masses 1,5 (7,755) Decrease (increase) in obsci masses, permanent aquity (2,24) (8,248) Purchase of face assets (0,274) (8,248) Purchase of face assets (2,12) (2,31)	Net income including non-controlling interest	\$	37,220	\$	43,407
Provision for credit losses 6,172 5,548 Beguiny-based wards compensation expense 7,236 7,240 Armonization of deb issue costs 4,409 300 Change in reschander of puriphy thaihing (2,582) 7 Conseg in deferred immosense duced at the dimension of the second at the dimension of the dimen		ig activities:	15 605		14 743
Figure-based awards composition expenses 7.256 7.260 Amontization of other size costs 4.20 305 Change in after value of continguit cancent availeration (2.82) 5 Change in a value of continguit cancent consideration (2.53) (6.67) Loss (gain) on set of collisis and fixed assets (6.67) (1.07) Loss (gain) on set of collisis and fixed assets (7.65) (0.67) Other - (83) Change in operating assets and labelities: - (83) Increase in pactoria accounts receivable (5.645) (0.279) Increase in accounts receivable (5.645) (0.279) Increase (increase) in other long-term labilities (2.54) 2.54 Vector browide by operating activities (2.53) (5.75) Event provide by operating activities (2.53) (2.53) (4.98) Proceeds on sale of part content covide acquired (2.53) (2.53) (2.54) Interest in broin accounts provide and accound expenses (2.61) (2.83) (2.82) Proceeds on sale of partoreaconting interest, termanet equity (,
Anotization of debi issue costs4,003.05Change in creaturation of put-right liability(2,582)5Change in creaturation of put-right liability(2,582)5Change in far value costiliance artificat(950)(1,643)Harris in an econstillated artificat(950)(1,643)Harris in an econstillated artificat(950)(1,643)Other-(8,645)(10,279)Increase in pacient accounts receivable - other(5,645)(10,279)Increase in accounts provide and account expenses(1,97)(5,540)Decrease (increase) in accounts payload mal accrued expenses(1,97)(5,540)Decrease (increase) in accounts payload mal accrued expenses(1,97)(5,540)Net each provided by operating activities81,97858,537INVESING ACTIVITIESPurchase of fungionity interest in basinesses, net of cash acquired(26,552)(89,788)Purchase of nagionity interest in basinesses, net of cash acquired(26,552)(26,978)Purchase of nagionity interest, respirary requiry(10,976)(14,987)Purchase of nagionity interest, respirary requiry(10,976)(14,987)Purchase of nagionity interest, respirary requiry(20,972)(20,972)Purchase of nagionity interest, respirary requiry(21,252)(22,122)Purchase of nagionity interest, respirary requiry(21,252)(22,122)Purchase of nagionity interest, respirary requiry(24,123)(21,253)Purchase of naccounties provided affiliat<					,
Change in far value of contingent ensourconsidentian (2,582) 5 Change in far value of contingent ensourconsidentian (955) (1,175) Loss (gain) on side of chines and fixed asets (166) (643) Changes in process (5,454) (10,279) Increase in potent accounts receivable (5,454) (10,279) Increase in accounts increavely and account expresses (157) (5,540) Decrease in accounts proceed and account expresses (157) (5,540) Decrease in accounts provide and account expresses (157) (5,540) Decrease in accounts provide and account expresses (127) (5,540) Decrease (increase) in other integenese (128) (2,530) Purchase of fixed assets (129) (2,530) (2,301) Purchase of fixed assets (12,02) (2,200) (2,200) Proceeds on all of partnership interest, remonant quity (10,201) (2,201) (2,201) Proceeds on all of partnership interest, remonant quity (10,201) (2,201) (2,212) Proceeds on all of partnership interest, remonant qquity (10,201) (11,202)			· · · · · · · · · · · · · · · · · · ·		,
Change in fir value of contingent eme-sut consideration 1,550 (2.220) Equity of a emage in unconsolidated assets 166 (643) Description 17,495 9,112 Change in flashing the assets 17,495 9,112 Other - (83) Description - (83) Increase in predicta accounts receivable: (546) (0,07) Increase (corresse) in other courtent and long-term assets (197) (5,540) Decrease ((norresse) in other courtent and long-term assets 15 (7,755) Decrease ((norresse) in other long-term liabilities 1,254 2,546 Net safe provided by operating activities 81,978 85,557 Net safe provided by operating activities (26,582) (9,284) Purchase of neightry interest, temporary equity (26,852) (29,284) Purchase of neightry interest, temporary equity (26,582) (49,285) Purchase of neightry interest, temporary equity (26,510) (28,249) Proceeds on asle of non-controlling interest, temporary equity (26,531) (49,285) Purchase of neightry in			4,490		4,309
Equity of earnings in unconsolidated affiliate(955)(1.175)Loss (gain) on sile of clinics and fixed assets166(643)Impairment of goodwill and their intragible usets17,4959,112Other.(83)Changes in operating assets and labilities:Increase in publical accounts receivable(36,645)(10,279)Increase in nuclean accounts receivable(37)(079)Decrease (increase) in outer long-term liabilities.15Vec ash provided by operating activities81,978\$8,537Net cash provided by operating activities81,978\$8,537INVESTING ACTIVITIESPurchase of fixed assets(20,532)(59,788)Purchase of fixed assetsPurchase of sole assetsProceeds on sile of purcershing interest, temporary equity102(20,80)Proceeds on sile of purcershing interest, temporary equityProceeds on sile of purcershing interest, elinies and fixed assetsProceeds from solution for uncost on the secondary public offering, net of issuanceOtherProceeds from issuance of common monoperativeProceeds from issuance of common monoperativeProceeds from issuance of common monoperative <td></td> <td></td> <td></td> <td></td> <td></td>					
Lose (gain) on sale of clinics and fixed assets166(643)Impairent of goodwill and other imagible assets17,9959,112Other-(83)Increase in patient accounts receivable(5,645)(10,279)Increase in accounts provide and accrued expenses(157)(5,546)Decrease (increase) in accounts provide and accrued expenses15(255)Decrease (increase) in accounts provide and accrued expenses15(255)INSUING ACCIVITIES81,978\$8,537INVESTING ACCIVITIES81,978(26,582)(9,294)Parchase of readorable indicates, net of each acquired(26,582)(9,294)Parchase of readorable non-controlling interest, temporary equity(10,986)(14,987)Parchase of non-controlling interest, temporary equity(21)(280)Proceeds on alse of partnership interest - redeemable non-controlling interest, temporary equity875402Proceeds from issuance of common stock pursuant equity(21)(81,299)Proceeds from issuance of common stock pursuant to the secondary public offering, net of issuance321-Proceeds from issuance of common stock pursuant to the secondary public offering, net of issuance(24,218)(21,211)Cast dividends paid to sharebolders-(12,31)(21,32)Proceeds from revolving facility(24,128)(21,211)(21,32)Proceeds from revolving facility(24,128)(21,211)(21,21)Prometer of the interest, eremporary equity(15,480)Proceeds from					
Impainment of goodwill and other intangible assets 9, 9,112 Other - (83) Changes in operating assets and liabilities: Increase in pattern accounts receivable (5,645) (10,279) Increase (increase) in other current and long-term assets (1977) (5,940) Decrease (increase) in other long-term insets (1977) (5,940) Decrease (increase) in other long-term insets (1977) (5,940) Decrease (increase) in other long-term insets (12,24) (2,246) Net cash provided by operating astivities (2,246) INVESTING ACTIVITIES Purchase of fixed assets (0,204) (8,248) Purchase of fixed assets (0,294) (19,978) Purchase of neuro-tontrolling interest, temporary equity (10,986) (14,987) Purchase of neuro-tontrolling interest, temporary equity (10,986) (14,987) Purchase of neuro-tontrolling interest, permanent equity (2,21) (280) Proceeds on sale of partnership interest, remporary equity (10,986) (12,978) Purchase of neuro-tontrolling interest, permanent equity (2,21) (2,20) Proceeds on sale of partnership interest, endporary equity (2,21) (2,20) Proceeds on sale of partnership interest, endporary equity (2,21) (2,20) Proceeds on sale of partnership interest, endporary equity (2,21) (2,20) Proceeds on sale of partnership interest, endporary equity (2,21) (2,20) Proceeds on sale of partnership interest, endporary equity (2,21) (2,20) Proceeds from insuance of common stock pursuant to the secondary public offering, net of issuance Proceeds from issuance of common stock pursuant to the secondary public offering, net of issuance Proceeds from issuance of common stock pursuant to the secondary public offering, net of issuance Proceeds from issuance of common stock pursuant to the secondary public offering, net of issuance Proceeds from issuance of common stock pursuant to the secondary public offering, net of issuance Proceeds from issuance of common stock pursuant to the secondary public offering, net of issuance Proceeds from issuance of common stock pursuant to the secondary public offering, net of issuance Proceeds f	Equity of earnings in unconsolidated affiliate				
Other (83) Changes in operating assets and liabilities: (10,279) Increase in pulient accounts receivable other (336) (307) Increase in accounts pulsed and accrued expenses (157) (5,543) Decrease (increase) in accounts pulsed and accrued expenses (157) (5,545) Decrease (increase) in other long-term liabilities (2,24) (2,545) INVESTING ACTIVITIES (0,294) (8,248) Purchase of fixed assets (0,294) (2,828) Purchase of nedematic non-controlling interest, termporary equity (10,966) (14,987) Purchase of nedematic non-controlling interest, termporary equity (22) (2,97,88) Purchase of nedematic non-controlling interest, termporary equity (230) (230) Proceeds on sile of purturching interest, element equity (45,015) (81,269) Proceeds from unconsoliduat of times and fixed assets - 373 Other 321 - 373 Proceeds from sistance of common stock pursuant to the secondary public offering, net of issuance (45,015) (81,269) Proceeds from issuance of common stock pursuant to the secondary public offe					
Charges in operating assets and liabilities: (5,645) (10,279) Increase in accounts receivable - other (356) (307) Decrease (increase) in other ournal dong-term assets (197) (5,540) Decrease (increase) in other ournal dong-term assets (137) (15,540) Decrease (increase) in other ournal dong-term assets (137) (15,540) Net eash provided by operating activities 81,978 58,557 INVESTING ACTIVITIES (2,648) (2,548) Parchase of fixed assets (2,638) (2,813) Proceeds on ono-controlling interest, temporary equity (10,986) (14,987) Purchase of redeerable non-controlling interest, temporary equity (2,81) (2,80) Proceeds on ono-controlling interest, temporary equity (2,81) (2,80) Proceeds on ono-controlling interest, temporary equity (300) (12,90) Distributions from unconsolidated affiliate - 373 Other - 321 - Proceeds from isstance of common stock pursuant to the secondary public offering, net of issuance (45,000) (10,100) Distributions to non-controlling interest, permanent and temporary equity (16,160) (13,2			17,495		,
Increase in patient accounts receivable (5,645) (10,279) Increase in accounts previous - other (356) (307) Increase (increase) in accounts payable and accrued expenses 15 (7,755) Decrease (increase) in accounts payable and accrued expenses 124 2,346 Vet cash provided by operating activities 81,978 58,537 INVESTING ACTIVITIES (2,248) (2,488) Purchase of fixed assets (9,294) (8,248) Purchase of near-controlling interest, temponry equity (10,086) (14,987) Purchase of near-controlling interest, temponry equity (2,810) (2,800) Purchase of partnership interest, ermancent equity (2,810) (2,800) Proceeds on sale of non-controlling interest, temponry equity 10 - Distributions instance of common stock pursuant to the secondary public offering, net of issuance - - Costs - 311 - - Proceeds from issuance of common stock pursuant to the secondary public offering, net of issuance - - - Costs - - 312 - - - Proceeds from revolving ficility <t< td=""><td></td><td></td><td></td><td></td><td>(05)</td></t<>					(05)
Increase in accounts receivable - other (356) (307) Increase (increase) in accounts payable and accrued expenses 15 (7,755) Decrease (increase) in other ourse mastets 15 (7,755) Decrease (increase) in other ourse mastets 81,978 55,537 INCENTING ACTIVITIES 7 7 Purchase of majority interest in businesses, et of cash acquired (26,582) (59,788) Purchase of majority interest in businesses, et of cash acquired (26,582) (59,788) Purchase of majority interest intermanent equity (28) (28) Purchase of majority interest intermanent equity (28) (28) Proceeds on sile of non-controlling interest, remporary equity 102 - Proceeds on sile of non-controlling interest, remporary equity 810 1,259 Proceeds on sile of non-controlling interest, remporary equity 810 1,259 Proceeds on sile of non-controlling interest, remporary equity 161,646 - Proceeds from revolving fincity 161,646 - - Proceeds from revolving fincity 161,646 - - - Pr			(5,645)		(10,279)
Decrease (increase) in accounts payable and accrued expenses 15 (17,75) Decrease (increase) in outer load-term liabilities 81,978 58,537 INUESTING ACTIVITIES (2,24) (2,24) Purchase of fixed assets (9,294) (8,248) Purchase of majority interest in businesses, net of cash acquired (2,05,82) (59,788) Purchase of non-controlling interest, temporary equity (10,986) (14,987) Proceeds on sale of partnership interest - redeemable non-controlling interest, permanent equity 830 1.259 Proceeds on sale of partnership interest - redeemable non-controlling interest, permanent equity 830 1.259 Proceeds on sale of partnership interest, etimosand fixed assets - 371 Other - 372 Proceeds from issuance of common stock pursuant to the secondary public offering, net of issuance 163,646 - Costs - 163,640 - - Proceeds from resolving facility (4,000) (14,287) (13,21) Partnership interest, permanent quity (24,128) (21,220) (21,220) Protecods from resolving facility - <td></td> <td></td> <td></td> <td></td> <td>(307)</td>					(307)
Decrease (increase) in other long-term liabilities1,2542,546Net cash provided by operating activities81,07858,537INVESTING ACTIVITIES(2,548)(3,248)Purchase of fixed assets(9,294)(8,248)Purchase of redeemable non-controlling interest, temporary equity(10,986)(14,987)Purchase of redeemable non-controlling interest, temporary equity102-Proceeds on sale of partership interest, relemable non-controlling interest, temporary equity875402Proceeds on sale of partership interest, relemable non-controlling interest, relemable non-controlling interest, temporary equity875402Distributions from unconsolidated affitiate-373301,259Proceeds on sale of partership interest, elinies and fixed assets373Other-321Net cash used in investing activities(16,500)(18,129)(8,1269)FINANCING ACTIVITIES-163,646Proceeds from revolving facility24,000101,000(15,348)(2,121)Cash advidends paid to shareholdersPayments on nevolving facility(6,400)(930)94,2000(10,120)(18,4200)Payment of deferred financing costsPayment of deferred financing costsInterest paid(3,1590)(1,1231)30,027<	Increase (decrease) in other current and long-term assets		(197)		(5,940)
Net cash provided by operating activities 81,978 58,537 INVESTING ACTIVITIES (2,24) (8,248) Purchase of Insed assis (26,582) (59,788) Purchase of Insed assis (26,582) (26,582) Purchase of Insed assis (26,582) (26,582) Purchase of Incedenable non-controlling interest, temporary equity (281) (280) Proceedes on sale of partnership interest - redocmable non-controlling interest, temporary equity 830 1.259 Proceeds on sale of partnership interest, elinics and fixed assets - 373 Other - 373 Proceeds from issuance of common stock pursuant to the secondary public offering, net of issuance (24,5015) (81,269) Proceeds from revolving facility (24,000) (10,000) (15,448) Proceeds from revolving facility (24,128) (21,211) Payments on revolving facility (3,500) (18,4000) Proceeds from setters bernamet and temporary equity (16,100) (15,448) Cash dividends paid to stancholders (24,128) (21,211) Proceeds from revolving facility (24,400)					(7,755)
INVESTING ACTIVITIES (8,248) Purchase of fixed assets (9,294) (8,248) Purchase of majority interest, insporary equity (10,986) (14,987) Purchase of non-controlling interest, permanent equity (281) (280) Proceeds on sale of non-controlling interest, permanent equity (102) - Proceeds on sale of partnership interest, remporary equity 875 400 Distributions from unconsolidated affinite 321 - Proceeds on sale of partnership interest, remporary equity (45,015) (81,299) FINANCING ACTIVITIES 733 - - Proceeds from issuance of common stock pursuant to the secondary public offering, net of issuance - - Costs 163,646 - - Proceeds from revolving facility 2(4,000) (10,000) 1(5,348) Distibutions to non-controlling interest, permanent and temporary equity (16,100) (15,348) Cash dividends paid to shareholders (24,128) (21,321) Proceeds from revolving facility 2(4,400) (9,300) Princitipal payrunets on notes payable (4,400)					,
Purchase of fixed assets(9,294)(8,248)Purchase of majority interest, temporary equity(10,986)(14,987)Purchase of redeemable non-controlling interest, temporary equity(281)(280)Proceeds on sale of non-controlling interest, temporary equity(87)402Proceeds on sale of partnership interest, erranent equity(87)402Distributions from unconsolidated affinities(81,02)(81,02)Other321Net eash used in investing activities(45,015)(81,269)FINANCING ACTIVITIES(45,015)(81,269)Proceeds from insuance of common stock pursuant to the secondary public offering, net of issuance-costs(16,100)(15,348)Proceeds from revolving facility24,000101,000Distributions to non-controlling interest, permanent and temporary equity(16,100)(15,348)Cash dividends paird of shareholders(24,128)(21,321)Payments on revolving facility(55,000)(184,000)Principal payments on notes payableProceeds from term loanProceeds from term loan </td <td>Net cash provided by operating activities</td> <td></td> <td>81,978</td> <td></td> <td>58,537</td>	Net cash provided by operating activities		81,978		58,537
Purchase of fixed assets(9,294)(8,248)Purchase of majority interest, temporary equity(10,986)(14,987)Purchase of redeemable non-controlling interest, temporary equity(281)(280)Proceeds on sale of non-controlling interest, temporary equity(87)402Proceeds on sale of partnership interest, erranent equity(87)402Distributions from unconsolidated affinities(81,02)(81,02)Other321Net eash used in investing activities(45,015)(81,269)FINANCING ACTIVITIES(45,015)(81,269)Proceeds from insuance of common stock pursuant to the secondary public offering, net of issuance-costs(16,100)(15,348)Proceeds from revolving facility24,000101,000Distributions to non-controlling interest, permanent and temporary equity(16,100)(15,348)Cash dividends paird of shareholders(24,128)(21,321)Payments on revolving facility(55,000)(184,000)Principal payments on notes payableProceeds from term loanProceeds from term loan </td <td>INVESTING ACTIVITIES</td> <td></td> <td></td> <td></td> <td></td>	INVESTING ACTIVITIES				
Purchase of majority interest in businesses, net of cash acquired (26,582) (59,788) Purchase of redernable non-controlling interest, termpary equity (10,986) (14,987) Proceeds on sale of non-controlling interest, termpart equity 102 - Proceeds on sale of non-controlling interest, termpart equity 875 402 Distributions from unconsolidated affiliate 830 1.259 Proceeds on sale of partnership interest, elimics and fixed assets - 373 Other 321 - Net cash used in investing activities (45,015) (81,269) FINANCING ACTIVITIES - - Proceeds from resolving facility 24,000 101,000 Distributions to non-controlling interest, permanent and temporary equity (16,160) (15,348) Cash dividends paid to shareholders - - Participal payments on netwoiving facility (24,128) (21,213) Payments on tervolving facility - - - Payments on tervolving facility - - - Payments on tervolving facility (3,750) (18,750) (18,4000) Principal payments on netwoiving facility <td></td> <td></td> <td>(9, 294)</td> <td></td> <td>(8, 248)</td>			(9, 294)		(8, 248)
Purchase of redeemable non-controlling interest, temporary equity (10,986) (14,987) Purchase of non-controlling interest, remporary equity 102 - Proceeds on sale of non-controlling interest, remporary equity 875 402 Distributions from unconsolidated affiliate 830 1.259 Proceeds on sale of partnership interest, clinics and fixed assets - 373 Other 221 - Net eash used in investing activities (45,015) (81,269) FINANCING ACTIVITIES 163,646 - Proceeds from revolving facility 24,000 101,000 Distributions to non-controlling interest, permanent and temporary equity (16,100) (13,348) Cash dividends paid to shareholders (24,128) (21,321) Payments on netwolving facility (3,750) (1,870) Proceeds from revolving facility (3,750) (1,84,000) Payments on networking activities - 150,000 Payments on term loan (3,750) (1,84,000) Payments on term loan - 120,000 Payments of deferred financing costs - - Payment of Medicare Accelerated a					
Purchase of non-controlling interest, permanent equity (281) (280) Proceeds on sale of non-controlling interest, permanent equity 102 - Proceeds on sale of partnership interest, erence equity 875 402 Distributions from unconsolidated affiliate 830 1,259 Proceeds on sale of partnership interest, clinics and fixed assets 321 - Other 321 - Net cash used in investing activities (45,015) (81,269) FINANCING ACTIVITIES - - Proceeds from revolving facility 24,000 101,000 Distributions to non-controlling interest, permanent and temporary equity (16,100) (15,348) Cash dividends paid to shareholders (24,128) (21,321) Payments on nevolving facility (55,000) (184,000) Payments on notes payable - - Proceeds from trem loan (3,750) (1,879) Payments on term loan - - 12 Payments of deferred financing costs - - 12 Net cash provided by financing activities \$ 4,268 225,507 Net cash and cash					
Proceeds on sale of non-controlling interest, permanent equity102.Proceeds on sale of partnership interest, redeemable non-controlling interest, temporary equity8301.259Proceeds on sale of partnership interest, clinics and fixed assets.373OtherNet eash used in investing activitiesFINANCING ACTIVITIESProceeds from issuance of common stock pursuant to the secondary public offering, net of issuancecostsProceeds from revolving facilityDistributions to non-controlling interest, permanent and temporary equity<					
Proceeds on sale of partnership interest, redeenable non-controlling interest, temporary equity875402Distributions from uncosolidated affiliate8301.259Proceeds on sale of partnership interest, clinics and fixed assets-373Other321-Net cash used in investing activities(45.015)(81.269)FINANCING ACTIVITIESProceeds from issuance of common stock pursuant to the secondary public offering, net of issuance163.646-Proceeds from revolving facility24.000101.000(15.348)Cash dividends paid to shareholders(24.128)(21.21)Payments on revolving facility(55.000)(184.000)Principal payments on notes payable(4.400)(930)Payment on term loan(3.750)(1.875)Proceeds from term loan-150.0000Payment of deferred financing costs-12Net cash provided by financing activities84.268225.759Net cash ap quivalents - end of period31.59428.677Cash and cash equivalents - end of period\$ 1.52,825\$ 31.594Suppression during the period for:Income taxes\$ 4.926\$ 5.587Notes payable related to purchase of redeenable non-controlling interest, temporary equity1.0871.074Notes payable related to purchase of non-controlling interest, temporary equity1.0871.074Notes payable related to purchase of non-controlling interest, temporary equity3002.657Notes payable related to purchase of non-controlling i					-
Proceeds on sale of partnership interest, clinics and fixed assets.373Other321.Net cash used in investing activities(45.015)(81.269)FINANCING ACTIVITIESProceeds from revolving facility24,000101,000Distributions to non-controlling interest, permanent and temporary equity(16,100)(15.348)Cash dividends paid to shareholders(24,128)(21,321)Payments on revolving facility(55.000)(184,000)Proceeds from true loan(3,750)(1.875)Proceeds from true loan(3,750)(1.875)Proceeds from true loan(3,750)(1.875)Proceeds from true loan(1.779)10,000Payment of Medicare Accelerated and Advance Funds-12Net cash provided by financing activities84,26825,759Net cash provided by financing activities121,2313,027Cash and cash equivalents121,2313,027Cash and cash equivalents - end of period\$152,825S31,59428,567S4,926\$7,615Income taxes\$4,926\$Income taxes\$4,926\$Paychas of burning period\$\$5,5687Notes payable related to purchase of redeemable non-controlling interest, temporary equity1,0071,074Notes payable related to the purchase of non-controlling interest, temporary equity1,0371,074Notes payable related to the purchase of non-controlling interest, tempo			875		402
Other321-Net cash used in investing activities(45,015)(81,269)FINANCING ACTIVITIESProceeds from issuance of common stock pursuant to the secondary public offering, net of issuancecosts163,646Proceeds from revolving facility24,000Distributions to non-controlling interest, permanent and temporary equity(16,100)Cliptical distributions to non-controlling interest, permanent and temporary equity(16,100)Cliptical distributions to non-controlling interest, permanent and temporary equity(16,100)Other (4,400)(930)Payments on notes payable(4,400)Payments on notes payable(18,750)Proceeds from term loan(3,750)(1,875)Proceeds from term loan(3,750)(1,875)Proceeds from free dinancing costs12Other-12Net cash provided by financing activities84,26825,759Net cash provided by financing activities\$121,2313,027Cash and cash equivalents121,2313,027Cash and cash equivalents\$1,54\$Purchase in cash and cash equivalents\$4,926\$7,615Income taxes\$4,926\$7,615Income taxes\$4,926			830		1,259
Net cash used in investing activities(45,015)(81,269)Froceeds from issuance of common stock pursuant to the secondary public offering, net of issuance costsProceeds from revolving facility24,000101,000Distributions to non-controlling interest, permanent and temporary equity(16,100)(15,348)Cash dividends paid to shareholders(24,128)(21,21)Payments on revolving facility(55,000)(184,000)Principal payments on notes payable(4,400)(930)Payments on term loan(3,750)(1,875)Proceeds from term loan-150,000Payment of deferred financing costsOther-1210000Net cash provided by financing activities84,26825,759Net increase in cash and cash equivalents121,2313,027Cash and cash equivalents - end of period\$152,825\$SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION\$4,926\$Cash paid during the period for: Income taxes\$4,926\$Purchase of businesses - seller financing portion\$1,815\$Notes payable related to purchase of a business524Notes payable related to purchase of a business524Notes payable related to the purchase of non-controlling interest, temporary equity1,0871,074Notes payable related to the purchase of non-controlling interest, temporary equity4,1361,586Notes payable related to the purchase of non-cont			-		373
FINANCING ACTIVITIES Proceeds from issuance of common stock pursuant to the secondary public offering, net of issuance 163,646 - costs 163,646 - Proceeds from revolving facility 24,000 101,000 Distributions to non-controlling interest, permanent and temporary equity (16,100) (15,348) Cash dividends paid to shareholders (24,128) (21,321) Payments on revolving facility (3,750) (184,000) Proceeds from term loan (3,750) (1,875) Proceeds from term loan - 150,000 Payment of deferred financing costs - 1 Other - 1 2 Net cash provided by financing activities 84,268 225,759 Net increase in cash and cash equivalents 121,231 3,027 Cash and cash equivalents 121,231 3,027 Cash and cash equivalents \$ 12,825 \$ SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION \$ 1,574 Cash paid during the period for: \$ 8,655 \$ Income taxes \$ 1,815 \$					-
Proceeds from issuance of common stock pursuant to the secondary public offering, net of issuancecosts163,646-Proceeds from revolving facility24,000101,000Distributions to non-controlling interest, permanent and temporary equity(16,100)(15,348)Cash dividends paid to shareholders(24,128)(21,321)Payments on revolving facility(55,000)(184,000)Principal payments on notes payable(4,400)(930)Payments on tron loan3(3,750)(1,875)Proceeds from term loan-150,000Payment of deferred financing costs-150,000Payment of Medicare Accelerated and Advance Funds-12Other-12Net cash provided by financing activities84,26825,759Net cash provided by financing activities121,2313,027Cash and cash equivalents131,59428,567SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION\$13,594Cash provided by epriod for: Income taxes\$4,926\$Income taxes\$4,926\$5,687Non-cash investing and financing transactions during the period: Purchase of businesses - seller financing portion\$1,514Notes payable related to purchase of non-controlling interest, temporary equity1,0871,074Notes payable related to the purchase of non-controlling interest, temporary equity4,1361,580	Net cash used in investing activities		(45,015)		(81,269)
Proceeds from issuance of common stock pursuant to the secondary public offering, net of issuancecosts163,646-Proceeds from revolving facility24,000101,000Distributions to non-controlling interest, permanent and temporary equity(16,100)(15,348)Cash dividends paid to shareholders(24,128)(21,321)Payments on revolving facility(55,000)(184,000)Principal payments on notes payable(4,400)(930)Payments on tron loan3(3,750)(1,875)Proceeds from term loan-150,000Payment of deferred financing costs-150,000Payment of Medicare Accelerated and Advance Funds-12Other-12Net cash provided by financing activities84,26825,759Net cash provided by financing activities121,2313,027Cash and cash equivalents131,59428,567SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION\$13,594Cash provided by epriod for: Income taxes\$4,926\$Income taxes\$4,926\$5,687Non-cash investing and financing transactions during the period: Purchase of businesses - seller financing portion\$1,514Notes payable related to purchase of non-controlling interest, temporary equity1,0871,074Notes payable related to the purchase of non-controlling interest, temporary equity4,1361,580	FINANCING ACTIVITIES				
costs163,646-Proceeds from revolving facility24,000101,000Distributions to non-controlling interest, permanent and temporary equity(16,100)(15,348)Cash dividends paid to shareholders(24,128)(21,321)Payments on revolving facility(35,000)(184,000)Principal payments on notes payable(4,400)(930)Proceeds from term loan(3,750)(1,875)Proceeds from term loan(3,750)(1,875)Payment of deferred financing costs-(1,779)Payment of Medicare Accelerated and Advance Funds-120,000Other120,000Net cash provided by financing activities84,26825,759Net increase in cash and cash equivalents121,2313,027Cash and cash equivalents - beginning of period\$152,825\$SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION\$\$5Cash provided by innecing transactions during the period:\$\$5,687Non-cash investing and financing transactions during the period:\$1,515\$Purchase of businesses - seller financing portion\$1,815\$1,574Liabilities assumed associated with a purchase of a business524Notes payable related to purchase of redeemable non-controlling interest, temporary equity1,0871,074Notes payable related to seler of a business226Notes payable related to one-controlling interest, temporary equity4,1361,580296					
Distributions to non-controlling interest, permanent and temporary equity $(16,100)$ $(15,348)$ Cash dividends paid to shareholders $(24,128)$ $(21,321)$ Payments on revolving facility $(55,000)$ $(184,000)$ Principal payments on notes payable $(4,400)$ (930) Payments on term loan $(3,750)$ $(1,875)$ Proceeds from term loan- $150,000$ Payment of deferred financing costs- $150,000$ Payment of deferred financing costs- $120,000$ Other $120,000$ Net cash provided by financing activities $84,268$ $225,759$ Net increase in cash and cash equivalents $31,594$ $28,567$ Cash and cash equivalents - beginning of period $$121,231$ $3,027$ Cash and cash equivalents - end of period $$152,825$ $$31,594$ SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION $$$4,926$ $$$7,615$ Increase in cash investing and financing transactions during the period: $$$$1,574$ Income taxes $$$$4,926$ $$$$7,615$ Interest paid $$$$1,815$ $$$$$1,574$ Votes payable related to with a purchase of a business $$$24$ -Purchase of businesses - seller financing portion $$$$1,815$ $$$$1,574$ Liabilities assumed associated with a purchase of a business $$$24$ -Notes payable related to the purchase of non-controlling interest, temporary equity $1,087$ $1,074$ Notes payable related to the purchase of non-controlling interest, temporary equity 200			163,646		-
Cash dividends paid to shareholders(24,128)(21,321)Payments on revolving facility(55,000)(184,000)Principal payments on notes payable(4,400)(930)Payments on term loan(3,750)(1,875)Proceeds from term loan-150,000Payment of deferred financing costs-(1,779)Payment of Medicare Accelerated and Advance FundsOther-12Net cash provided by financing activities84,26825,759Net cash provided by financing of period121,2313,027Cash and cash equivalents121,2313,027Cash and cash equivalents - beginning of period\$152,825SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION\$84,266Cash paid during the period for: Income taxes\$4,926\$Non-cash investing and financing transactions during the period: Purchase of businesses - seller financing portion\$1,815\$Notes payable related to business of non-controlling interest, temporary equity1,0871,074Notes payable related to to the purchase of non-controlling interest, temporary equity200296Notes payable related to a lot of nedeemable non-controlling interest, temporary equity4,1361,580			24,000		101,000
Payments on revolving facility(55,000)(184,000)Principal payments on tern loan(4,400)(930)Payments on tern loan(3,750)(1,875)Proceeds from tern loan-150,000Payment of deferred financing costs-(1,779)Payment of Medicare Accelerated and Advance Funds-12Other12Net cash provided by financing activities84,26825,759Net increase in cash and cash equivalents121,2313,027Cash and cash equivalents - beginning of period $\frac{31,594}{$}$ 28,567Cash and cash equivalents - or or and of period\$152,825\$SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATIONCash paid during the period fo:Income taxes\$4,926\$7,615Interest paid\$\$8,655\$5,687Not-eash investing and financing transactions during the period:Purchase of businesses - seller financing portion\$1,815\$1,574Liabilities assumed associated with a purchase of a business524Notes payable related to the purchase of non-controlling interest, permanent equity1,0871,0741,074Notes receivable related to able of redeemable non-controlling interest, temporary equity4,1361,5801,580			(16,100)		(15,348)
Principal payments on notes payable $(4,400)$ (930) Payments on term loan $(3,750)$ $(1,875)$ Proceeds from term loan $ 150,000$ Payment of deferred financing costs $ (1,779)$ Payment of Medicare Accelerated and Advance Funds $ (1,779)$ Payment of Medicare Accelerated and Advance Funds $ 12$ Other $ 12$ Net cash provided by financing activities $84,268$ $25,759$ Net increase in cash and cash equivalents $121,231$ $3,027$ Cash and cash equivalents - beginning of period $\frac{3}{5}$ $152,825$ $\frac{$}{$}$ Cash and cash equivalents - end of period $\frac{$}{$}$ $152,825$ $\frac{$}{$}$ SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION $\frac{$}{$}$ $4,926$ $\frac{$}{$}$ $7,615$ Interest paid $\frac{$}{$}$ $4,926$ $\frac{$}{$}$ $7,615$ Interest paid $\frac{$}{$}$ $4,926$ $\frac{$}{$}$ $7,615$ Non-cash investing and financing transactions during the period: $\frac{$}{$}$ $1,815$ $\frac{$}{$}$ $1,574$ Liabilities assumed associated with a purchase of a business 524 $ -$ Notes payable related to purchase of non-controlling interest, temporary equity $1,087$ $1,074$ Notes receivable related to the purchase of non-controlling interest, temporary equity $4,136$ $1,580$					
Payments on term loan $(3,750)$ $(1,875)$ Proceeds from term loan-150,000Payment of deferred financing costs- $(1,779)$ Payment of Medicare Accelerated and Advance Funds- $(1,779)$ Other-12Net cash provided by financing activities $84,268$ $25,759$ Net cash provided by financing operations121,231 $3,027$ Cash and cash equivalents121,231 $3,027$ Cash and cash equivalents - beginning of period $$15,945$ \$SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION\$ $$152,825$ \$Cash priod for: Income taxes\$4,926\$7,615Interest paid\$\$8,655\$5,687Non-cash investing and financing portion\$1,815\$1,574Liabilities assumed associated with a purchase of a business524Notes payable related to purchase of redeemable non-controlling interest, temporary equity1,0871,074Notes payable related to the purchase of non-controlling interest, temporary equity200296Notes payable related to the purchase of non-controlling interest, temporary equity200296Notes payable related to the purchase of non-controlling interest, temporary equity4,1361,580	Payments on revolving facility				
Proceeds from term loan150,000Payment of deferred financing costs-(1,779)Payment of Medicare Accelerated and Advance FundsOtherNet cash provided by financing activities84,26825,759Net increase in cash and cash equivalents121,2313,027Cash and cash equivalents - beginning of period31,59428,567Cash and cash equivalents - of period\$152,825\$SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION\$152,825\$Cash paid during the period for: Income taxes\$4,926\$7,615Interest paid\$8,655\$5,687Non-cash investing and financing portion\$1,815\$1,574Liabilities assumed associated with a purchase of a business524Notes payable related to purchase of redeemable non-controlling interest, temporary equity1,0871,074Notes receivable related to sale of redeemable non-controlling interest, temporary equity4,1361,580					
Payment of deferred financing costs-(1,779)Payment of Medicare Accelerated and Advance FundsOther12Net cash provided by financing activities84,26825,759Net increase in cash and cash equivalents121,2313,027Cash and cash equivalents - beginning of period31,59428,567Cash and cash equivalents - end of period\$152,825\$SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION\$4,926\$7,615Cash paid during the period for: Income taxes\$4,926\$7,615Non-cash investing and financing transactions during the period: Purchase of businesses - seller financing portion\$1,815\$1,574Liabilities assumed associated with a purchase of a business524Notes payable related to purchase of redeemable non-controlling interest, temporary equity1,0871,074.074Notes payable related to sale of redeemable non-controlling interest, temporary equity200296.296Notes receivable related to sale of redeemable non-controlling interest, temporary equity4,1361,580			(3,750)		
Payment of Medicare Accelerated and Advance FundsOther-12Net cash provided by financing activities84,26825,759Net increase in cash and cash equivalents121,2313,027Cash and cash equivalents - beginning of period31,59428,567Cash and cash equivalents - end of period\$152,825\$SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATIONCash paid during the period for: Income taxes\$4,926\$7,615Interest paid\$8,655\$5,687Non-cash investing and financing transactions during the period: Purchase of businesses - seller financing portion\$1,815\$1,574Liabilities assumed associated with a purchase of a business524Notes payable related to purchase of non-controlling interest, temporary equity1,0871,0741,074Notes payable related to the purchase of non-controlling interest, temporary equity200296296Notes receivable related to sale of redeemable non-controlling interest, temporary equity4,1361,580			-		
Other-12Net cash provided by financing activities $84,268$ $25,759$ Net increase in cash and cash equivalents $121,231$ $3,027$ Cash and cash equivalents - beginning of period $21,231$ $3,027$ Cash and cash equivalents - end of period $$152,825$ $$$31,594$ SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION $$$$152,825$ $$$$31,594$ Cash paid during the period for: Income taxes $$$$4,926$ $$$$7,615$ Income taxes $$$$4,926$ $$$$7,615$ Non-cash investing and financing transactions during the period: Purchase of businesses - seller financing portion $$$$1,815$ $$$$1,574$ Liabilities assumed associated with a purchase of a business 524 -Notes payable related to purchase of non-controlling interest, temporary equity $1,087$ $1,074$ Notes receivable related to the purchase of non-controlling interest, temporary equity 200 296 Notes receivable related to sale of redeemable non-controlling interest, temporary equity $4,136$ $1,580$			-		(1,779)
Net cash provided by financing activities84,26825,759Net increase in cash and cash equivalents121,2313,027Cash and cash equivalents - beginning of period31,59428,567Cash and cash equivalents - end of period\$152,825\$SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATIONCash paid during the period for: Income taxes\$4,926\$7,615Interest paid\$8,655\$5,687Non-cash investing and financing transactions during the period: Purchase of businesses - seller financing portion\$1,815\$1,574Liabilities assumed associated with a purchase of a business524Notes payable related to purchase of redeemable non-controlling interest, temporary equity1,0871,0741,074Notes receivable related to sale of redeemable non-controlling interest, temporary equity200296Notes receivable related to sale of redeemable non-controlling interest, temporary equity4,1361,580			-		12
Net increase in cash and cash equivalents $121,231$ $3,027$ Cash and cash equivalents - beginning of period $31,594$ $28,567$ Cash and cash equivalents - end of period $\$$ $152,825$ $\$$ SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATIONCash paid during the period for: Income taxes $\$$ $4,926$ $\$$ $7,615$ Interest paid $\$$ $8,655$ $\$$ $5,687$ Non-cash investing and financing transactions during the period: Purchase of businesses - seller financing portion $\$$ $1,815$ $\$$ $1,574$ Liabilities assumed associated with a purchase of a business 524 Notes payable related to purchase of redeemable non-controlling interest, temporary equity $1,087$ $1,074$ Notes receivable related to sale of redeemable non-controlling interest, temporary equity 200 296 Notes receivable related to sale of redeemable non-controlling interest, temporary equity $4,136$ $1,580$			84,268		
Cash and cash equivalents - beginning of period31,59428,567Cash and cash equivalents - end of period\$ 152,825\$ 31,594SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATIONCash paid during the period for: Income taxes\$ 4,926\$ 7,615Income taxes\$ 4,926\$ 7,615Interest paid\$ 8,655\$ 5,687Non-cash investing and financing transactions during the period: Purchase of businesses - seller financing portion Liabilities assumed associated with a purchase of a business Notes payable related to purchase of redeemable non-controlling interest, temporary equity\$ 1,815\$ 1,574Notes payable related to the purchase of redeemable non-controlling interest, temporary equity200296Notes receivable related to sale of redeemable non-controlling interest, temporary equity4,1361,580			<u> </u>		
Cash and cash equivalents - end of period\$152,825\$31,594SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATIONCash paid during the period for: Income taxes\$4,926\$7,615Interest paid\$8,655\$5,687Non-cash investing and financing transactions during the period: Purchase of businesses - seller financing portion Liabilities assumed associated with a purchase of a business Notes payable related to purchase of redeemable non-controlling interest, temporary equity Notes receivable related to sale of redeemable non-controlling interest, temporary equity1,0871,074Notes receivable related to sale of redeemable non-controlling interest, temporary equity200296Notes receivable related to sale of redeemable non-controlling interest, temporary equity4,1361,580					· · · · ·
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Cash paid during the period for: Income taxes \$ 4,926 \$ 7,615 Interest paid \$ 8,655 \$ 5,687 Non-cash investing and financing transactions during the period: \$ 1,815 \$ 1,574 Purchase of businesses - seller financing portion \$ 1,815 \$ 1,574 Liabilities assumed associated with a purchase of a business 524 - Notes payable related to purchase of redeemable non-controlling interest, temporary equity 1,087 1,074 Notes receivable related to sale of redeemable non-controlling interest, temporary equity 200 296 Notes receivable related to sale of redeemable non-controlling interest, temporary equity 4,136 1,580					
Cash paid during the period for: Income taxes\$4,926\$7,615Incerest paid\$8,655\$\$5,687Non-cash investing and financing transactions during the period: Purchase of businesses - seller financing portion\$1,815\$1,574Liabilities assumed associated with a purchase of a business524-Notes payable related to purchase of redeemable non-controlling interest, temporary equity1,0871,074Notes receivable related to sale of redeemable non-controlling interest, temporary equity200296Notes receivable related to sale of redeemable non-controlling interest, temporary equity4,1361,580	Cash and cash equivalents - end of period	\$	152,825	\$	31,594
Cash paid during the period for: Income taxes\$4,926\$7,615Incerest paid\$8,655\$\$5,687Non-cash investing and financing transactions during the period: Purchase of businesses - seller financing portion\$1,815\$1,574Liabilities assumed associated with a purchase of a business524-Notes payable related to purchase of redeemable non-controlling interest, temporary equity1,0871,074Notes receivable related to sale of redeemable non-controlling interest, temporary equity200296Notes receivable related to sale of redeemable non-controlling interest, temporary equity4,1361,580	SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION				
Income taxes\$4,926\$7,615Interest paid\$8,655\$5,687Non-cash investing and financing transactions during the period:1,815\$Purchase of businesses - seller financing portion\$1,815\$1,574Liabilities assumed associated with a purchase of a business524-Notes payable related to purchase of redeemable non-controlling interest, temporary equity1,0871,074Notes receivable related to sale of redeemable non-controlling interest, temporary equity200296Notes receivable related to sale of redeemable non-controlling interest, temporary equity4,1361,580					
Interest paid\$8,655\$5,687Non-cash investing and financing transactions during the period:1,815\$1,574Purchase of businesses - seller financing portion\$1,815\$1,574Liabilities assumed associated with a purchase of a business524-Notes payable related to purchase of redeemable non-controlling interest, temporary equity1,0871,074Notes payable related to the purchase of non-controlling interest, permanent equity200296Notes receivable related to sale of redeemable non-controlling interest, temporary equity4,1361,580		\$	4,926	\$	7.615
Non-cash investing and financing transactions during the period: 9 1,815 \$ 1,574 Purchase of businesses - seller financing portion \$ 1,815 \$ 1,574 Liabilities assumed associated with a purchase of a business 524 - Notes payable related to purchase of redeemable non-controlling interest, temporary equity 1,087 1,074 Notes payable related to the purchase of non-controlling interest, permanent equity 200 296 Notes receivable related to sale of redeemable non-controlling interest, temporary equity 4,136 1,580			· · ·		
Purchase of businesses - seller financing portion\$1,815\$1,574Liabilities assumed associated with a purchase of a business524-Notes payable related to purchase of redeemable non-controlling interest, temporary equity1,0871,074Notes payable related to the purchase of non-controlling interest, permanent equity200296Notes receivable related to sale of redeemable non-controlling interest, temporary equity4,1361,580	Non-cash investing and financing transactions during the period:		,		
Notes payable related to purchase of redeemable non-controlling interest, temporary equity1,0871,074Notes payable related to the purchase of non-controlling interest, permanent equity200296Notes receivable related to sale of redeemable non-controlling interest, temporary equity4,1361,580	Purchase of businesses - seller financing portion	\$	1,815	\$	1,574
Notes payable related to the purchase of non-controlling interest, permanent equity200296Notes receivable related to sale of redeemable non-controlling interest, temporary equity4,1361,580	Liabilities assumed associated with a purchase of a business				-
Notes receivable related to sale of redeemable non-controlling interest, temporary equity 4,136 1,580			· · ·		,
Notes receivable related to the sale of non-controlling interest, permanent equity \$ 458 \$ -		¢		¢	1,580
	ivoles receivable related to the sale of non-controlling interest, permanent equity	\$	458	2	-

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES ADJUSTED EBITDA AND OPERATING RESULTS (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

The following tables provide details of the basic and diluted earnings per share computation and reconcile net income attributable to USPH shareholders calculated in accordance with GAAP to Adjusted EBITDA and Operating Results (non-GAAP measures). Management believes providing Adjusted EBITDA and Operating Results to investors is useful information for comparing the Company's period-to-period results.

Adjusted EBITDA, a non-GAAP measure, is defined as net income attributable to USPH shareholders before interest income, interest expense, taxes, depreciation, amortization, non-cash asset impairment charge, change in fair value of contingent earn-out consideration, Relief Funds, changes in revaluation of put-right liability, equity-based awards compensation expense, and related portions for non-controlling interests.

Operating Results, a non-GAAP measure, equals net income attributable to USPH shareholders less non-cash asset impairment charge, changes in revaluation of put-right liability, Relief Funds, changes in fair value of contingent earn-out consideration, and any allocations to non-controlling interests, all net of taxes. Operating Results per share also exclude the impact of the revaluation of redeemable non-controlling interest and the associated tax impact.

Management uses Adjusted EBITDA and Operating Results, which eliminate certain items described above that can be subject to volatility and unusual costs, as the principal measures to evaluate and monitor financial performance period over period. Management believes that Adjusted EBITDA and Operating Results are useful measures for investors to use in comparing the Company's period-to-period results as well as for comparing with other similar businesses since most do not have redeemable instruments and therefore have different equity structures.

Adjusted EBITDA and Operating Results are not measures of financial performance under GAAP. Adjusted EBITDA and Operating Results should not be considered in isolation or as an alternative to, or substitute for, net income attributable to USPH shareholders presented in the consolidated financial statements.

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES ADJUSTED EBITDA, OPERATING RESULTS AND EARNINGS PER SHARE (IN THOUSANDS, EXCEPT PER SHARE DATA)

	Fou	rth Quarter En	ded Decen	1ber 31,	Fo	r the Year Ende	d Decemb	d December 31,	
		2023		2022		2023		2022	
			(In	thousands, exce	ept per sha	re data)			
Adjusted EBITDA (a non-GAAP measure)	<u>^</u>		¢	2 (07	<u>^</u>		^		
Net income attributable to USPH shareholders	\$	656	\$	2,607	\$	28,239	\$	32,158	
Adjustments:		1 200		1 0 1 0		10.154		10.144	
Provision for income taxes		1,399		1,212		12,156		12,164	
Depreciation and amortization		4,113		3,793		15,695		14,743	
Interest expense, debt and other, net		2,010		2,239		9,303		5,779	
Interest income from investments		(1,583)		-		(3,774)		-	
Impairment of goodwill and other intangible assets		17,495		9,112		17,495		9,112	
Equity-based awards compensation expense		1,785		1,802		7,236		7,264	
Change in revaluation of put-right liability		(2,926)		776		(2,582)		5	
Change in fair value of contingent earn-out consideration		1,747		(520)		1,550		(2,520)	
Relief Funds		-		-		(467)		-	
Other income		(85)		(69)		(390)		(859)	
Allocation to non-controlling interests		(5,625)		(3,098)		(6,744)		(4,185)	
	\$	18,986	\$	17,854	\$	77,717	\$	73,661	
Operating Results (a non-GAAP measure)									
Net income attributable to USPH shareholders	\$	656	\$	2,607	\$	28,239	\$	32,158	
Adjustments:									
Impairment of goodwill and other intangible assets		17,495		9,112		17,495		9,112	
Change in fair value of contingent earn-out consideration		1,747		(520)		1,550		(2,520)	
Change in revaluation of put-right liability		(2,926)		776		(2,582)		5	
Relief Funds		-		-		(467)		-	
Allocation to non-controlling interest		(5,249)		(2,734)		(5,215)		(2,734)	
Tax effect at statutory rate (federal and state)		(2,828)		(1,695)		(2,755)		(987)	
	\$	8,895	\$	7,546	\$	36,265	\$	35,034	
Operating Results per share (a non-GAAP measure)	\$	0.59	\$	0.58	\$	2.56	\$	2.70	
Earnings per share									
Computation of earnings per share - USPH shareholders:									
Net income attributable to USPH shareholders	\$	656	\$	2,607	\$	28,239	\$	32,158	
Charges to retained earnings:				,		-,		- ,	
Revaluation of redeemable non-controlling interest		(8,577)		(3,697)		(13,565)		(3,890)	
Tax effect at statutory rate (federal and state)		2,191		945		3,466		994	
Tux effect at statutory face (reactar and state)	\$	(5,730)	\$	(145)	\$	18,140	\$	29,262	
Earnings per share (basic and diluted)	\$	(0.38)	\$	(0.01)		1.28	\$	2.25	
Lamage per share (busic and anatea)	Ψ	(0.50)	Ψ	(0.01)	Ψ	1.20	Ψ	2.23	

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES REVENUE METRICS

	Number	of Clinics	Net Ra Patient		Patient V	visits ⁽¹⁾	Average Daily Visits Per Clinic ⁽¹⁾		
	2023	2022	2023	2022	2023	2022	2023	2022	
First quarter	647	601	\$103.12	\$103.00	1,227,490	1,063,519	29.8	27.9	
Second quarter	656	608	\$102.03	\$103.18	1,267,140	1,145,554	30.4	29.5	
Third quarter	672	614	\$102.37	\$104.01	1,242,954	1,122,070	29.7	28.8	
Fourth quarter	671	640	\$103.68	\$104.28	1,267,842	1,152,139	29.9	29.1	
Year	671	640	\$102.80	\$103.63	5,005,426	4,483,282	30.0	28.7	

(1) See definition of the metrics above in the *Glossary of Terms – Revenue Metrics* on page 7.

Clinic Count Roll Forward

	Fourth Quarter Endeo	l December 31,	Year Ended December 31,			
	2023	2022	2023	2022		
Number of clinics, beginning of period	672	614	640	591		
Additions	6	32	46	65		
Closed or sold	(7)	(6)	(15)	(16)		
Number of clinics, end of period	671	640	671	640		